After a thorough and comprehensive review of proposals received from suppliers of viral marker testing platforms and assays, CTS has decided to convert to the Ortho VERSEIA Integrated Processor (VIP) viral marker testing platform and associated assays in January 2021. An exact conversion date will be provided when available. We are confident that the VERSIA system will allow us to continue delivering on our commitment to support our clients in their life-saving mission.
Read all about it on the Communication page by clicking this link: Communications
In response to the FDA guidance document for Babesia, CTS will implement the licensed Grifols ...
The CTS 2020 Annual Laboratory Survey is on its way to your email box. We would appreciate you takin...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
As previously mentioned in Zika communications distributed on September 21 and October 12, 2018; ord...
CTS Spotlight at 2018 AABB Annual Meeting Sunday, October 14, 2018 at 1:30 PM: Scientific Oral ...
The CTS Medical Advisory Board recently agreed upon a revision to our standard testing algorithm thi...